GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MYND Life Sciences Inc (XCNQ:MYND) » Definitions » EV-to-EBIT

MYND Life Sciences (XCNQ:MYND) EV-to-EBIT : -10.36 (As of May. 05, 2024)


View and export this data going back to 2021. Start your Free Trial

What is MYND Life Sciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, MYND Life Sciences's Enterprise Value is C$4.91 Mil. MYND Life Sciences's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 was C$-0.47 Mil. Therefore, MYND Life Sciences's EV-to-EBIT for today is -10.36.

The historical rank and industry rank for MYND Life Sciences's EV-to-EBIT or its related term are showing as below:

XCNQ:MYND' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.35   Med: -1.1   Max: -0.65
Current: -10.35

During the past 3 years, the highest EV-to-EBIT of MYND Life Sciences was -0.65. The lowest was -10.35. And the median was -1.10.

XCNQ:MYND's EV-to-EBIT is ranked worse than
100% of 434 companies
in the Biotechnology industry
Industry Median: 8.915 vs XCNQ:MYND: -10.35

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. MYND Life Sciences's Enterprise Value for the quarter that ended in Jan. 2024 was C$3.96 Mil. MYND Life Sciences's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 was C$-0.47 Mil. MYND Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2024 was -11.98%.


MYND Life Sciences EV-to-EBIT Historical Data

The historical data trend for MYND Life Sciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MYND Life Sciences EV-to-EBIT Chart

MYND Life Sciences Annual Data
Trend Oct21 Oct22 Oct23
EV-to-EBIT
-10.43 -2.09 -4.73

MYND Life Sciences Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.18 -1.86 -2.09 -4.73 -8.35

Competitive Comparison of MYND Life Sciences's EV-to-EBIT

For the Biotechnology subindustry, MYND Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MYND Life Sciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MYND Life Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where MYND Life Sciences's EV-to-EBIT falls into.



MYND Life Sciences EV-to-EBIT Calculation

MYND Life Sciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=4.912/-0.474
=-10.36

MYND Life Sciences's current Enterprise Value is C$4.91 Mil.
MYND Life Sciences's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MYND Life Sciences  (XCNQ:MYND) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

MYND Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jan. 2024 ) =EBIT / Enterprise Value (Q: Jan. 2024 )
=-0.474/3.956344
=-11.98 %

MYND Life Sciences's Enterprise Value for the quarter that ended in Jan. 2024 was C$3.96 Mil.
MYND Life Sciences's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MYND Life Sciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of MYND Life Sciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


MYND Life Sciences (XCNQ:MYND) Business Description

Traded in Other Exchanges
Address
05-2248 Elgin Ave., Port Coquitlam, BC, CAN, V3C 2B2
MYND Life Sciences Inc is a medical biotech drug research and development company. The company is focused on neuro pharmaceutical and novel drug development, diagnostics, and vaccines and is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by different molecular concepts for the applications of psilocybin analogs for overcoming diseases.

MYND Life Sciences (XCNQ:MYND) Headlines

From GuruFocus

Mynd.ai, Inc. Consummates Merger Transaction

By PRNewswire 12-13-2023